Search for: "Takeda Pharmaceuticals International AG"
Results 1 - 19
of 19
Sorted by Relevance
|
Sort by Date
21 May 2015, 8:25 am
However, in information released at trial, internal studies by the pharmaceutical manufacturer as far back as 2004 linked the drug to an increased risk in bladder cancer. [read post]
21 May 2015, 8:25 am
However, in information released at trial, internal studies by the pharmaceutical manufacturer as far back as 2004 linked the drug to an increased risk in bladder cancer. [read post]
21 May 2015, 8:25 am
However, in information released at trial, internal studies by the pharmaceutical manufacturer as far back as 2004 linked the drug to an increased risk in bladder cancer. [read post]
21 May 2015, 8:25 am
However, in information released at trial, internal studies by the pharmaceutical manufacturer as far back as 2004 linked the drug to an increased risk in bladder cancer. [read post]
15 Nov 2017, 8:00 am
It does not offend traditional notions of fair play and substantial justice, International Shoe v. [read post]
1 Dec 2017, 11:35 am
Bard in Q2 2017 helped increase the value of deals.[27] Takeda Pharmaceutical Company acquired ARIAD Pharmaceuticals Inc for $5.2 billion to expand its oncology business. [read post]
18 Jan 2024, 9:16 am
Lundbeck A/S, Takeda Pharmaceutical Company Ltd., Takeda Pharmaceuticals U.S.A., Inc., Takeda Pharmaceuticals International AG, and Takeda Pharmaceuticals America, Inc.) sued to enjoin Defendants from marketing generic versions on the basis of inducing and/or contributorily infringing various patents, including U.S. [read post]
3 May 2016, 9:00 pm
Guest Post By: Paul Dietze and Mini Kapoor, Haynes and Boone, LLP[1] On March 18, 2016, the Federal Circuit held that Mylan Pharmaceuticals, Inc. [read post]
29 Mar 2011, 9:19 pm
New pharmaceutical compulsory licenses proposed for patented medicines (Patentology) (ipwars) Canada: Election drum beats the life out of Access to Medicines Bill (IP Osgoode) EU opines on the patentability of human embryonic stem cells: Brüstle v Greenpeace (Kluwer Patent Blog) (IPBiz) EU: In the ECJ this week: Case C-195/09 Synthon v Merz Pharma and Case C-427/09 Generics (UK) v Synaptech (The SPC Blog) India: The production of generic drugs in India: A new trade agreement with the… [read post]
2 Apr 2015, 7:32 am
Takeda Pharmaceuticals, Asia’s largest drugmaker, has offered to pay more than $2.2 billion to settle claims that it hid the cancer risks associated with its Actos diabetes medicine. [read post]
28 Jul 2015, 11:52 am
Takeda Pharms. [read post]
26 Apr 2021, 7:42 am
Moderna also entered into deals with Catalent Inc. and Baxter International Inc. to help fill vaccine vials, and Takeda will use an existing facility in Japan to manufacture, import, and distribute vaccines. [read post]
18 Mar 2010, 2:30 am
Mylan Pharmaceuticals, Inc. et al. [read post]
19 Mar 2015, 5:00 am
Novartis AG, ___ F. [read post]
30 Apr 2019, 7:22 am
Final panellist Jürgen Dressel (ex- Novartis Pharma AG) explained that, going back to basics, the SPC is meant to be a reward for R&D and there should be legal certainty and a harmonised situation for the international market. [read post]
26 Jan 2010, 7:06 am
Elliott ** Editor, Time International, Time Magazine, USA Panellists Dennis Nally ** Chairman, PricewaterhouseCoopers International, PricewaterhouseCoopers, USA Arif M. [read post]
24 Sep 2010, 1:15 pm
Altana Pharma AG v. [read post]
13 Jun 2008, 3:40 am
’ – London: (IPKat), 18 June: CC technology summit – California: (creativecommons.org), 18-20 June: IIR generic drugs summit – Washington: (Orange Book Blog), 18-20 June / 9-11 July: US PLI: ‘Fundamentals of patent prosecution 2008: A boot camp for claim drafting & amendment writing’ – New York / San Francisco: (Patent Docs), 19-20 June: 27th ECTA Conference ‘Forty shades of green: a tour of the IP… [read post]
28 Apr 2008, 11:00 am
You can separately subscribe to the IP Thinktank Global week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: CAFC vacates FTC’s decision that Rambus breached antitrust duty by violating JEDEC patent disclosure rules and orders new trial: (Philip Brooks), (Techdirt), (Ars Technica), (IP Law360), (Peter Zura's 271 Patent Blog), (Hal Wegner), (IPBiz), (IP Law360), UK Court of Appeal rules on whether prior art not in the same design field… [read post]
